Christin Glorioso

Christin Glorioso is an MIT-trained neuroscientist, physician, and entrepreneur with expertise in AI and computational modeling.

She created the #1 US COVID case prediction model out of 104 global teams from leading institutions, including Columbia University and MILA, and companies such as Microsoft, in the XPRIZE Pandemic Response Challenge. While serving as Head of Research at the MIT spinout DICE Institute, her predictions were used in the WHO-backed Karuna App, which had 23 million downloads during the Delta COVID wave in India. The app saved countless lives by connecting people to sources of oxygen in regions where supplies were limited. Her predictions were also used by physician colleagues in the United States to anticipate hospital staffing needs during COVID outbreaks.

Christin is a pioneer of aging clocks in the human brain, which form the basis of her longevity techbio startup, NeuroAge Therapeutics. The company helps people track and reverse brain aging through comprehensive testing and science-backed recommendations personalized to their biomarkers and genetics. NeuroAge is an alumnus of the Berkeley SkyDeck Accelerator, a winner of the National Institute on Aging Startup Challenge, an MBC BioLabs Golden Ticket sponsored by AbbVie, and the Stanford Longevity Company Competition. The company is backed by the Alzheimer’s Drug Discovery Foundation and is currently recruiting patients with MCI and early Alzheimer’s disease for its lifestyle study. Free NeuroAge testing is available, and interested participants are encouraged to get in touch.

She is passionate about community building and also serves as the Founder and Executive Director of Longevity Global, a nonprofit organization that connects longevity researchers, investors, and entrepreneurs in the San Francisco Bay Area, New York City, San Diego, Boston, Phoenix, Miami, Switzerland, the UAE, and other expanding locations.